Credit score: Nature Chemical Biology (2025). DOI: 10.1038/s41589-025-01998-x
A group of Northwestern investigators has found novel molecular underpinnings of a standard oncogenic mutation in most cancers, findings that will inform the event of recent therapeutic methods, in response to findings revealed in Nature Chemical Biology.
Shana Kelley, Ph.D., the Neena B. Schwartz Professor of Chemistry, Biomedical Engineering, and Biochemistry and Molecular Genetics, was senior writer of the research. Kelley can also be the president of the Chan Zuckerberg Biohub Chicago.
One of the vital generally mutated oncogenes in most cancers, KRAS mutations are seen in pancreatic most cancers, colon most cancers and non-small cell lung most cancers, amongst others. Mutations of KRAS have lengthy been targets of curiosity for the event of recent most cancers therapies, however structural adjustments brought on by these mutations have made it significantly tough to focus on and inhibit.
Earlier analysis efforts have aimed to focus on one particular KRAS mutation, KRAS-G12C, which has proven promising ends in treating tumors. These findings motivated Kelley’s group to research one other KRAS mutation, KRAS-G12V, and determine genes that specifically modulate KRAS-G12V protein ranges that might then be therapeutically focused.
“What we decided is that rather than trying to get a small molecule to attack those amino acids specifically, let’s try to find a gene or a protein that actually regulates the levels of that mutated protein,” Kelley stated.
By conducting genome-wide CRISPR–Cas9-mediated knockout screens in wild-type and KRAS-G12V cell traces, the scientists found that cells expressing the gene ELOVL6 had decrease KRAS-G12V protein expression.
They discovered that ELOVL6, a fatty acid elongase, is concerned within the manufacturing of the cell plasma membrane, and the lipid that ELOVL6 helps produce is the place KRAS-G12V “anchors” itself, Kelley stated.
“When we hit this lipid elongase, it selectively took out the lipid that the mutated KRAS liked, and so then the mutated form of the protein falls off the membrane and it gets degraded and it gets kicked out of the cell,” stated Kelley, who can also be a member of the Robert H. Lurie Complete Most cancers Heart of Northwestern College. “That was the big discovery; very unexpected.”
Subsequent, the scientists discovered that giving mice with KRAS-G12V-mutated tumors an ELOVL6-inhibitor demonstrated a discount in tumor development and improved survival.
These findings might inform the event of recent mutation-specific therapeutic methods for treating mutant KRAS-driven cancers, Kelley stated.
“We were able to show that this was potentially a way that a new therapy could be created,” Kelley stated. “We’re working now on a startup company where we’ll be able to take that forward and see if it’s a new approach for oncology.”
Extra info:
Xiyue Hu et al, ELOVL6 exercise attenuation induces mutant KRAS degradation, Nature Chemical Biology (2025). DOI: 10.1038/s41589-025-01998-x
Supplied by
Northwestern College
Quotation:
Uncovering new therapeutic targets for a standard KRAS mutation behind most cancers (2025, October 27)
retrieved 28 October 2025
from https://medicalxpress.com/information/2025-10-uncovering-therapeutic-common-kras-mutation.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
